8-K: Olema Oncology Unveils Strong Palazestrant Combo Data

Olema Pharmaceuticals announced encouraging Phase 1b/2 trial data for palazestrant combined with ribociclib in ER+/HER2metastatic breast cancer, showing compelling progression-free survival and favorable tolerability.

Summary

• New data from the Phase 1b/2 trial of palazestrant in combination with ribociclib in ER+/HER2advanced or metastatic breast cancer was announced.
• 72 patients were enrolled across 90 mg and 120 mg palazestrant dose cohorts, all receiving 600 mg ribociclib daily.
• 63% of patients (45/72) had prior treatment with CDK4/6 inhibitors and endocrine therapy for advanced disease.
• In the 120 mg palazestrant cohort, with a median follow-up of over 19 months, median Progression-Free Survival (mPFS) was 15.5 months for all patients.
• For patients with prior CDK4/6i treatment, mPFS was 12.2 months, including 9.2 months for ESR1 wild-type tumors and 13.8 months for ESR1 mutant tumors.
• The combination was well tolerated with no new safety signals or increased toxicity, consistent with the established safety profile of ribociclib plus endocrine therapy.
• The majority of treatment-emergent adverse events were Grade 1 or 2.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial data for palazestrant, showing compelling efficacy and a favorable safety profile in a challenging patient population. The data supports ongoing pivotal Phase 3 trials and positions the drug as a potential best-in-class therapy. The company also highlights a strong pipeline and significant market opportunities, indicating strong future prospects.

Positives

• Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups.
• Median PFS of 15.5 months for all patients in the 120 mg palazestrant cohort is a compelling result.
• Strong mPFS of 13.8 months in ESR1 mutant tumors and 9.2 months in ESR1 wild-type tumors among patients previously treated with CDK4/6i, addressing a challenging patient population.
• The combination showed favorable tolerability and a safety profile consistent with the known profiles of each drug, with no new safety signals or increase in toxicity.
• No drug-drug interactions were observed between palazestrant and ribociclib.
• Data supports the ongoing pivotal Phase 3 OPERA-02 trial, reinforcing the regimen's potential as a new standard of care.
• Palazestrant has FDA Fast Track designation for ER+/HER2metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.
• The company is advancing OP-3136, a potent and selective KAT6 inhibitor, which has shown synergistic activity with palazestrant in preclinical models.

Risks

• Statements regarding future events are forward-looking and subject to various risks and uncertainties.
• Actual results, performance, or achievements could differ materially from those described or implied.
• Risks and uncertainties include those discussed in the 'Risk Factors' section of Olema's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and other SEC filings.
• Risks inherent in developing products and technologies.
• Uncertainty of future results from ongoing and planned clinical trials.
• Ability to obtain adequate financing to fund clinical trials and other expenses.
• Uncertainty regarding regulatory matters, including timing and likelihood of drug approvals and securing approved indications.
• Risks associated with cross-trial comparisons of publicly available third-party data, which may not be independently verified and should be interpreted with caution due to differences in study design and reporting.

Future Outlook

The company anticipates significant progress with its pipeline, including top-line data from the pivotal Phase 3 OPERA-01 trial in H2 2026, and from the pivotal Phase 3 OPERA-02 trial in 2028. Potential FDA approval and U.S. launch for palazestrant monotherapy in 2/3L ER+/HER2MBC is expected in 2027, with label expansion for the combination therapy in 1L MBC by 2029. Initial clinical results for the novel KAT6 inhibitor, OP-3136, are expected in 2026, with a potential Phase 3 trial around 2028. The company projects a global market opportunity of over $20 billion for its ER+/HER2MBC therapies and OP-3136.

Management Comments

• "We are very pleased with these latest data showing compelling progression-free survival and favorable tolerability of palazestrant plus ribociclib, further reinforcing this regimen's potential as a new standard of care in metastatic breast cancer."
• "These data showcase the activity of the combination in both ESR1 mutant and wild-type tumors, an important component for effective frontline treatment, and underscore the importance of complete ER antagonism in the treatment of ER-positive breast cancer."
• "As we work to transform the breast cancer treatment paradigm, we are increasingly confident in palazestrant's potential to become a best-in-class, backbone endocrine therapy and are excited to now have our second Phase 3 trial, OPERA-02, underway evaluating palazestrant with ribociclib in the frontline setting."

Industry Context

Despite recent advances in treating ER+/HER2metastatic breast cancer, there remains a significant need for therapies that can overcome endocrine resistance, especially after CDK4/6 inhibitor treatment. The presented data for palazestrant in combination with ribociclib, particularly its favorable comparison to other endocrine therapy-CDK4/6 inhibitor combinations and its activity in both ESR1 mutant and wild-type tumors, positions it as a promising agent to address this unmet need and potentially transform the breast cancer treatment paradigm. The company aims for palazestrant to become a best-in-class, backbone endocrine therapy.

Comparison to Industry Standards

• The palazestrant + ribociclib combination's safety profile was consistent with the established label of ribociclib + endocrine therapy, as seen in the MONALEESA-2 trial (Letrozole + Ribociclib).
• In CDK4/6i pre-treated patients, the 120 mg palazestrant + ribociclib cohort showed a median PFS of 12.2 months, which compares favorably to: MAINTAIN study ET + Placebo (2.7 months) and ET + Ribociclib (6.9 months); MORPHEUS Giredestrant + Ribociclib (6.9 months); ELEVATE Elacestrant + Ribociclib (6.0 months); SERENA-1 Camizestrant + Ribociclib (600 mg) (8.0 months).
• Palazestrant monotherapy in EMERALD-eligible 2/3L patients demonstrated a median PFS of 7.3 months in ESR1 mutant tumors and 5.5 months in ESR1 wild-type tumors, which compares favorably to: EMERALD Control Arm (3.8 months); Elacestrant (EMERALD) (3.8 months); Giredestrant (acelERA) (5.5 months for 75mg, 3.8 months for 150mg); Imlunestrant (EMBER-3) (6.0 months); Vepdegestrant (Veritac-2) (5.5 months).
• The company draws a parallel to TAGRISSO's path to approval and label expansion by suppressing resistance mutations (EGFR T790M), suggesting OPERA-02 is designed to achieve similar success by suppressing ESR1 mutations.
• OP-3136 preclinical data demonstrated superior selectivity over other essential KAT family members (KAT5 and KAT8) compared to Pfizer's KAT6 inhibitor PF-8144, potentially offering a safety advantage.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for new standard of care, significant market opportunities, and clear development pathway for multiple assets.
• Patients: Potential for a new, effective, and well-tolerated treatment option for ER+/HER2metastatic breast cancer, especially for those who have progressed on prior therapies.
• Medical Community: Provides encouraging data for a novel combination therapy that could address unmet needs in breast cancer treatment, particularly for ESR1 mutant and wild-type tumors.
• Employees: Positive outlook for job security and growth within a company advancing promising therapies.
• Competitors: May face increased competition from a potentially best-in-class therapy.

Next Steps

• Continue patient enrollment in pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L MBC.
• Continue pivotal Phase 3 OPERA-02 trial of palazestrant + ribociclib in 1L MBC.
• Initiate combination study with Pfizer's atirmociclib (PF-07220060) in H2 2025.
• Advance patient enrollment in Phase 1 study of OP-3136 monotherapy and combination in advanced or metastatic ER+/HER2breast cancer, castrate-resistant prostate cancer, and non-small cell lung cancer.
• Anticipate initial monotherapy and combination data from the Phase 1 study of OP-3136 in 2026.
• Anticipate top-line results from OPERA-01 in H2 2026.
• Anticipate submission of New Drug Application (NDA) for palazestrant monotherapy in 2/3L MBC in 2027.
• Prepare for commercial launch of palazestrant monotherapy in 2/3L MBC in 2027.
• Anticipate top-line results from OPERA-02 in 2028.
• Anticipate label expansion for palazestrant in 1L MBC based on OPERA-02 in 2029.

Key Dates

Recommendation

The filing presents exceptionally strong Phase 1b/2 data for palazestrant in combination with ribociclib, demonstrating compelling median Progression-Free Survival (mPFS) across various patient subgroups, including those previously treated with CDK4/6 inhibitors. The mPFS of 15.5 months for all patients and 12.2 months for prior CDK4/6i patients (with 13.8 months for ESR1 mutant tumors) significantly outperforms current benchmarks and competitor data in this challenging metastatic breast cancer setting. The favorable safety and tolerability profile, coupled with the drug's FDA Fast Track designation and the clear pathway to pivotal Phase 3 trials (OPERA-01 and OPERA-02) with anticipated approvals by 2027-2029, de-risks the development considerably. The company also highlights a substantial global market opportunity exceeding $20 billion and a promising early-stage asset (OP-3136). These factors collectively indicate a high probability of commercial success and significant future value creation, making it a strong buy for long-term investors.

Keywords

Palazestrant, Ribociclib, Metastatic Breast Cancer, ER+ HER2-, CDK4/6 inhibitor, ESR1 mutation, Progression-Free Survival, Clinical Trial, Oncology, Biopharmaceutical, OP-3136, KAT6 inhibitor